share_log

Novavax | 8-K: Confidential Settlement Agreements and Release Agreements

Novavax | 8-K: Current report

诺瓦瓦克斯医药 | 8-K：重大事件
SEC announcement ·  03/26 16:07
Moomoo AI 已提取核心信息
Novavax, Inc. has entered into a settlement agreement with Fujifilm entities to resolve disputes over payments due under a previous agreement. The dispute arose from a Confidential Settlement Agreement and Release effective September 30, 2022, which required Novavax to pay up to $185 million to Fujifilm for the cancellation of manufacturing activities at FUJIFILM Diosynth Biotechnologies Texas, LLC. The final two payments totaling $68.6 million were contested by Novavax, leading to an arbitration demand by Fujifilm. The new settlement, reached on March 21, 2024, involves Novavax paying $42 million to Fujifilm and includes a mutual release of claims and the dismissal of the ongoing arbitration. This settlement will be detailed in Novavax's upcoming Quarterly Report on Form 10-Q for the quarter ending March 31, 2024.
Novavax, Inc. has entered into a settlement agreement with Fujifilm entities to resolve disputes over payments due under a previous agreement. The dispute arose from a Confidential Settlement Agreement and Release effective September 30, 2022, which required Novavax to pay up to $185 million to Fujifilm for the cancellation of manufacturing activities at FUJIFILM Diosynth Biotechnologies Texas, LLC. The final two payments totaling $68.6 million were contested by Novavax, leading to an arbitration demand by Fujifilm. The new settlement, reached on March 21, 2024, involves Novavax paying $42 million to Fujifilm and includes a mutual release of claims and the dismissal of the ongoing arbitration. This settlement will be detailed in Novavax's upcoming Quarterly Report on Form 10-Q for the quarter ending March 31, 2024.
Novavax, Inc.已与富士胶片各实体签订了和解协议，以解决有关根据先前协议到期付款的争议。该争议源于一份自2022年9月30日起生效的保密和解协议和新闻稿，该协议要求Novavax向富士胶片支付高达1.85亿美元，以取消德克萨斯州富士胶片迪奥辛斯生物技术有限责任公司的制造活动。最后两笔总额为6,860万美元的款项受到Novavax的质疑，导致富士胶片提出仲裁要求。新的和解协议于2024年3月21日达成，涉及Novavax向富士胶片支付4200万美元，其中包括相互发布索赔和驳回正在进行的仲裁。该和解协议将在Novavax即将发布的截至2024年3月31日的季度10-Q表季度报告中详细介绍。
Novavax, Inc.已与富士胶片各实体签订了和解协议，以解决有关根据先前协议到期付款的争议。该争议源于一份自2022年9月30日起生效的保密和解协议和新闻稿，该协议要求Novavax向富士胶片支付高达1.85亿美元，以取消德克萨斯州富士胶片迪奥辛斯生物技术有限责任公司的制造活动。最后两笔总额为6,860万美元的款项受到Novavax的质疑，导致富士胶片提出仲裁要求。新的和解协议于2024年3月21日达成，涉及Novavax向富士胶片支付4200万美元，其中包括相互发布索赔和驳回正在进行的仲裁。该和解协议将在Novavax即将发布的截至2024年3月31日的季度10-Q表季度报告中详细介绍。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息